VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
VBIV was delisted on the 7th of August, 2024.
95 hedge funds and large institutions have $27.9M invested in VBI Vaccines, Inc. New Common Stock (Canada) in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 20 increasing their positions, 34 reducing their positions, and 19 closing their positions.
3,650% more call options, than puts
Call options by funds: $75K | Put options by funds: $2K
14% less funds holding
Funds holding: 111 → 95 (-16)
24% less capital invested
Capital invested by funds: $36.7M → $27.9M (-$8.76M)
41% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 34
84% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$117K |
| 2 |
Morgan Stanley
New York
|
+$60.3K |
| 3 |
JP Morgan Chase
New York
|
+$56.3K |
| 4 |
Renaissance Technologies
New York
|
+$53.4K |
| 5 |
Barclays
London,
United Kingdom
|
+$22K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$273K |
| 2 |
Millennium Management
New York
|
-$176K |
| 3 |
Jane Street
New York
|
-$116K |
| 4 |
E
Ergoteles
New York
|
-$83.8K |
| 5 |
HF
HRT Financial
New York
|
-$82K |
VBIV Hedge Fund Activity: Q1 2023 in Review
95 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) for Q1 2023, worth a combined $27.9M — down 24% from $36.7M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of VBIV and 3 opened new positions — a net loss of 16 holders — while 34 trimmed existing stakes and 20 added.
The largest buyer was Bank of America, adding an estimated $117K. The largest seller was BlackRock, cutting an estimated $273K.
- 95 institutional investors held VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) as of Q1 2023, down from 111 in Q4 2022.
- Funds reported $27.9M of VBI Vaccines, Inc. New Common Stock (Canada) stock for Q1 2023, down 24% quarter-over-quarter.
- 3 funds opened new VBI Vaccines, Inc. New Common Stock (Canada) positions in Q1 2023 and 19 closed out, a net change of -16 holders.
- The largest VBI Vaccines, Inc. New Common Stock (Canada) buyer in Q1 2023 was Bank of America, an estimated $117K added.
- The largest VBI Vaccines, Inc. New Common Stock (Canada) seller in Q1 2023 was BlackRock, an estimated $273K sold.
Based on aggregated 13F filings for Q1 2023.